top of page

Mon, May 13


Kansas City, Missouri

CLSI Breakpoint Revisions (morning)

Registration is not yet available. Check back soon!
See other events
CLSI Breakpoint Revisions (morning)
CLSI Breakpoint Revisions (morning)

Time & Location

May 13, 2019, 7:45 AM – 12:00 PM

Kansas City, Missouri, 4401 Wornall Rd, Kansas City, MO 64111, USA

About The Event

CLSI Breakpoint Revisions: Why, How and What Should My Lab Do About Them?

Speaker: Romney Humphreys, PhD, D(ABMM)

Location: St Luke’s Hospital , PLAZA Board Rooms A, B & C (Conference rooms are on Level B)

Sponsors: St. Luke's Health System and Accelerate Diagnostics

SWACM Coordinators: LaNae Druen - and Chris Fuller -

***Non-member registration includes a 2019 membership.***


7:30 – 7:45 Registration

7:45 - 8:30 Overview of breakpoint setting organizations and US breakpoint legislation

8:30 – 9:15 Review breakpoints revised by CLSI since 2010, including drug classes and current epidemiology

9:15 – 9:30 Break - Refreshments

9:30 – 10:00 Cephalosporin revisions

10:00–10:30 Carbapenem revisions

10:30–11:00 2019 breakpoint revisions

11:00–12:00 Case studies on how to address breakpoint revisions, Q&A


This workshop is designed for clinical microbiologists, infectious diseases physicians, pharmacists and trainees or anyone who wants to improve their expertise in this critical area of laboratory medicine.

Antimicrobial resistance is a continually evolving challenge for laboratorians, physicians and pharmacists alike. CLSI has updated several breakpoints to address these challenges, however these updates are not universally adopted by laboratories. This workshop will review breakpoints updated by CLSI since 2010, starting with Enterobacteriaceae cephalosporin and carbapenem breakpoints, and ending with updates made to M100 S19 for 2019. Methods to prioritize and implement the breakpoints will be discussed.


After attendance, participants will be able to:

1. Define a clinical breakpoint for susceptibility testing

2. Discuss breakpoints revised since 2010 by CLSI, including 2019 revisions to the fluoroquinolones, daptomycin and ceftaroline

3. Prioritize breakpoint revisions within their institution

4. Develop a plan to update breakpoints on their AST systems


SWACM is approved as a Provider of Continuing Education Programs in Clinical Laboratory Sciences by the ASCLS P.A.C.E.® Program. Completion of this program will provide 4.0 contact hours of continuing education. SWACM programs are approved for California-licensed clinical laboratory scientists and personnel. The instructional level of this program is intermediate.


Romney Humphries, PhD, D(ABMM) is the Chief Scientific Officer of Accelerate Diagnostics and a Professor of Laboratory Medicine and the University of Arizona . She serves as a member of the CLSI AST Subcommittee and has published extensively on best practices for laboratories to address antimicrobial resistance challenges.


  • Member Registration

  • Non-Member Registration

    Includes 2019 SWACM membership

  • Student Registration




Share This Event

bottom of page